There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
Transcript
Are there unique challenges that community practices face in regard to reimbursement?
There have been a number of reforms that have tried to level the playing field in reimbursement. In 2015 the Bipartisan Budget Act instituted site neutrality on a go forward basis for off-campus outpatient facilities. Since then, there’s been an expansion to clinic office line visits and that could go further. But by in large today, there’s still a big disparity in reimbursement where a hospital practice or hospital-based cancer care center will receive twice as much as the outpatient facility does for the exact same service. And what this is doing is incentivizing hospitals to consolidate, and we will have situations where a community cancer center changes nothing but the sign on the door and now all of a sudden, the patient out-of-pocket cost has gone up and the cost of Medicare has gone up.
The administration—Secretary Azar and President Trump—has indicated that they want to look into this. They made a proposal in the last physician fee schedule. They want to explore site neutrality for drug administration services; that was included in the drug pricing blueprint. And this is also something that Congress is becoming well aware of in trying to figure out how they can expand what they passed in 2015, try to come to some sort of parity in reimbursement without disrupting access to care in hospital or community-based settings.
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More